Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05840510 · ClinicalTrials.gov registry record · Phase 1
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
A Phase 1 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05840510 is a Phase 1 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT05840510, a Phase 1 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
Interventions
- DRUG nab-Sirolimus
- DRUG Adagrasib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-08-07 |
| Est. Completion | 2024-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05840510
The ClinicalTrials.gov registry entry for NCT05840510 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nab-Sirolimus is the first listed.
NCT05840510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05840510 about?
NCT05840510 is a clinical study titled "Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)". This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
What is the current status of trial NCT05840510?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-08-07. Estimated completion is 2024-12-27.
What interventions are being tested in trial NCT05840510?
The interventions under investigation include: nab-Sirolimus (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT05840510?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.